Maria Creignou - Concepedia

Author

Maria Creignou

Karolinska University Hospital ORCID

Also Known As

M Creignou, M. Creignou, Maria Creignou

228

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Karolinska University Hospital Karolinska Institutet Humanitas University Istituti di Ricovero e Cura a Carattere Scientifico Kyoto University

About

Maria Creignou is an author at Karolinska University Hospital specializing in molecular diagnostics, medicine, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.4K
2	Health Sciences	2	2	630
3	Public Health	1	1	746
4	Biostatistics	1	1	746
5	Cell Biology	1	1	606

Maria Creignou

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes Elsa Bernard, Heinz Tuechler, Peter L. Greenberg, NEJM Evidence Mixed-phenotype Acute LeukemiaPrognosisGenetic EpidemiologyDiagnosisPathology	2022	746
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Nature Medicine Hematological MalignancyChromatinGenome StabilityMedicineMixed-phenotype Acute Leukemia	2020	606
Molecular taxonomy of myelodysplastic syndromes and its clinical implications Elsa Bernard, Robert P. Hasserjian, Peter L. Greenberg, Blood	2024	52
Molecular and clinical presentation of <i>UBA1</i>-mutated myelodysplastic syndromes Maria Sirenko, Elsa Bernard, Maria Creignou, Blood	2024	43
<i>ZBTB33</i> Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing Ellen M. Beauchamp, Matthew Leventhal, Elsa Bernard, Blood Cancer Discovery	2021	42
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms Gabriele Todisco, Maria Creignou, Anna Gallì, Leukemia Tumor BiologyDisease PhenotypeSomatic VariantTumor HeterogeneityMedicine	2020	33
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study Noffar Bar, María‐Victoria Mateos, Paz Ribas, Blood	2023	31
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms Yasuhito Nannya, Magnus Tobiasson, Shinya Sato, Blood Advances Mixed-phenotype Acute LeukemiaGeneticsPathologyMyeloid NeoplasiaHematological Malignancy	2023	24
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes Elsa Bernard, Yasuhito Nannya, Tetsuichi Yoshizato, Blood	2019	21
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register Stina Söderlund, Torsten Dahlén, Fredrik Sandin, European Journal Of Haematology	2016	18

Page 1